Author: Gottesdiener, Keith M. ; Wagner, John A. ; Simpson, Richard C. ; Marbury, Thomas ; Miller, Jutta L. ; Kari, Prasad P. ; Rodrigues, A. David ; Winchell, Gregory A. ; Mistry, Goutam C.

The effect of a clin. relevant dosing regimen of ketoconazole on the single-dose pharmacokinetics of L-771,688, a potent and highly selective α_1A-adrenoceptor antagonist was studied.Plasma concentrations of L-771,688 were significantly higher when a single-dose of L-771,688 was administered during a multiple-dose regimen of ketoconazole.The terminal half-life of L-771,688 was only moderately longer in the presence of ketoconazole.The moderate change in half-life is consistent with the prediction that metabolic clearance would be limited by liver blood even in the presence of substantial inhibition.Qual., the results suggest that ketoconazole primarily affected the first-pass elimination, and therefore bioavailability, of L-771,688 and had only a minor effect on the systemic clearance of L-771,688.The magnitude of the interaction implies that the bioavailability of L-771,688 in humans is well below 5% in the absence of ketoconazole.

01 Dec 2000·European Journal of PharmacologyQ3 · MEDICINE

In vitro studies on L-771,688 (SNAP 6383), a new potent and selective α1A-adrenoceptor antagonist

Q3 · MEDICINE

Article

Author: Wong, W. C. ; Murali Dhar, T. G. ; Tyagarajan, S. ; Marzabadi, M. R. ; Chang, R. S. L. ; Shen, Q. ; Chen, T.-B. ; Nagarathnam, D. ; Forray, C. ; O'Malley, S. S. ; Miao, S. W. ; Pettibone, D. J. ; Freidinger, R. ; DiSalvo, J. ; Bock, M. G. ; Francis, B. ; Gluchowski, C. ; Lagu, B.

L-771,688 (SNAP 6383, methyl(4S)-4-(3, 4-difluorophenyl)-6-[(methyloxy)methyl]-2-oxo-3-[(¿3-[4-(2-pyridin yl)-1-piperidinyl]propyl¿amino)carbonyl]-1,2,3, 4-tetrahydro-5-pyrimidine carboxylate) had high affinity (Ki less than or = 1 nM) for [3H]prazosin binding to cloned human, rat and dog alpha1A-adrenoceptors and high selectivity (>500-fold) over alpha1B and alpha1D-adrenoceptors. [3H]Prazosin / (+/-)-beta-[125I]-4-hydroxy-phenyl)-ethyl-aminomethylteralone ([125I]HEAT) binding studies in human and animal tissues known to contain alpha1A and non-alpha1A-adrenoceptors further demonstrated the potency and alpha1A-subtype selectivity of L-771,688. [3H]L-771,688 binding studies at the cloned human alpha1A-adrenoceptors and in rat tissues indicated that specific [3H]L-771,688 binding was saturable and of high affinity (Kd=43-90 pM) and represented binding to the pharmacologically relevant alpha1A-adrenoceptors. L-771,688 antagonized norepinephrine-induced inositol-phosphate responses in cloned human alpha1A-adrenoceptors, as well as phenylephrine or A-61603 (N-[5-4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7, 8-terahydro-naphthlen-1-yl] methanesulfonamide hydrobromide) induced contraction in isolated rat, dog and human prostate, human and monkey bladder neck and rat caudal artery with apparent Kb values of 0.02-0.28 nM. In contrast, the contraction of rat aorta induced by norepinephrine was resistant to L-771,688. These data indicate that L-771,688 is a highly selective alpha1A-adrenoceptor antagonist.

100 Deals associated with L-771688

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Hyperplasia	Phase 2	US	Lundbeck Research USA, Inc.	-
Prostatic Hyperplasia	Phase 2	-	Merck Sharp & Dohme Corp.	-
Prostatic Hyperplasia	Phase 2	-	H. Lundbeck A/S	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

L-771688

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation